Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial
Bots ML, Visseren FL, Evans GW, Riley WA, Revkin JH, Tegeler CH, Shear CL, Duggan WT, Vicari RM, Grobbee DE, Kastelein JJ, Investigators F. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. The Lancet 2007, 370: 153-160. PMID: 17630038, DOI: 10.1016/s0140-6736(07)61088-5.Peer-Reviewed Original ResearchConceptsIntima-media thicknessMaximum intima-media thicknessCarotid intima-media thicknessDouble-blind trialSystolic blood pressureCombined-treatment groupMixed dyslipidaemiaCholesteryl ester transfer proteinHDL cholesterolLipoprotein cholesterolBlood pressureLDL cholesterolCarotid segmentsHigh low-density lipoprotein cholesterolLow high-density lipoprotein cholesterolMaximum carotid intima-media thicknessHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolCarotid atherosclerosis progressionDose of treatmentYearly rateEster transfer proteinDose titrationPrimary endpointAtherosclerosis progressionEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. New England Journal Of Medicine 2007, 356: 1304-1316. PMID: 17387129, DOI: 10.1056/nejmoa070635.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticholesteremic AgentsAtorvastatinBlood PressureCardiovascular DiseasesCholesterol Ester Transfer ProteinsCholesterol, HDLCholesterol, LDLCoronary Artery DiseaseDisease ProgressionDouble-Blind MethodDrug Therapy, CombinationFemaleHeptanoic AcidsHumansMaleMiddle AgedProspective StudiesPyrrolesQuinolinesUltrasonography, InterventionalConceptsAtheroma volumeHDL cholesterolLDL cholesterolAtorvastatin monotherapyCoronary atherosclerosisLipoprotein cholesterolBlood pressureIntravascular ultrasonographyHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolEffects of torcetrapibCholesteryl ester transfer protein inhibitorsPercent atheroma volumeSystolic blood pressureHDL cholesterol levelsLack of efficacyCETP inhibitor torcetrapibMechanism of actionCardiovascular riskSmall favorable effectCholesterol levelsDisease progressionDiseased vessel segmentDrug classesSecondary measures